Monoamine metabolites as predictors of antidepressant response: a critique.
Monoamine metabolite measurements are being increasingly used for making nosological, symptomatological and pharmacological profiles of the affective disorders. A number of unresolved methodological issues question the validity of using baseline metabolite levels for predicting treatment response. Some studies show correlations between baseline metabolite levels and response to treatment with specific antidepressant agents. Effects of antidepressant treatment on metabolite levels may be useful in predicting drug response.
D000928:Antidepressive Agents / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects; D003866:Depressive Disorder / Q000188:drug therapy* / Q000201:enzymology; D004299:Dopamine beta-Hydroxylase / Q000097:blood; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008734:Methoxyhydroxyphenylglycol / Q000378:metabolism; D008995:Monoamine Oxidase / Q000097:blood; D018377:Neurotransmitter Agents / Q000378:metabolism*; D009638:Norepinephrine / Q000652:urine; D009647:Normetanephrine / Q000652:urine; D011941:Receptors, Adrenergic / Q000187:drug effects; D011985:Receptors, Serotonin / Q000187:drug effects; D014642:Vanilmandelic Acid / Q000652:urine
D000928:Antidepressive Agents; D018377:Neurotransmitter Agents; D011941:Receptors, Adrenergic; D011985:Receptors, Serotonin; D009647:Normetanephrine; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D014642:Vanilmandelic Acid; D004299:Dopamine beta-Hydroxylase; D008995:Monoamine Oxidase; D009638:Norepinephrine; D006719:Homovanillic Acid